Nexgel NXGL
NASDAQ NXGL
$4.25 +0.67 (+18.56%)
As of: Nov 11, 2026 · 1:55 PM EST

Nexgel (NXGL) Interest Coverage Ratio (2020 - 2024)

Updated

Nexgel's (NXGL) Interest Coverage Ratio came in at -98.59 for FY2025, compared with -43.88 in FY2024.

Analysis

Nexgel (NXGL) Interest Coverage Ratio (2020 - 2024) Analysis & Trends

Since FY2022, Nexgel has reported Interest Coverage Ratio for 4 years.

  • Annual Interest Coverage Ratio has run from a low of -231.80 in FY2023 to a high of -2.51 in FY2022 over five years.
  • Business Quant data shows NXGL's Interest Coverage Ratio at -43.88 in FY2024, -231.80 in FY2023 and -2.51 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Iqvia Holdings 45.36 Bn 36.74 Bn 1.50 Bn 2.82
2 Medpace Holdings 18.58 Bn 16.23 Bn 223.89 Mn -
3 Charles River Laboratories International 16.56 Bn 15.80 Bn 357.87 Mn 7.10
4 Icon 15.67 Bn 12.44 Bn 491.83 Mn 3.00
5 Fortrea Holdings 2.06 Bn 1.35 Bn 139.50 Mn -
6 Ginkgo Bioworks Holdings 774.61 Mn 39.09 Mn 25.91 Mn -
7 Evotec SE 600.89 Mn -1.16 Bn - -
8 Champions Oncology 66.11 Mn 41.77 Mn 7.70 Mn -
9 MindWalk Holdings 48.11 Mn 11.77 Mn 1.61 Mn -
10 Nexgel 1.74 Mn -3.57 Mn 1.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -60.07
Sep 30, 2024 -39.40
Jun 30, 2024 -35.13
Mar 31, 2024 -58.07
Dec 31, 2023 -609.50
Sep 30, 2023 -204.00
Jun 30, 2023 -84.67
Mar 31, 2023 -883.00
Dec 31, 2022 -390.50
Sep 30, 2022 -4.29
Jun 30, 2022 -2.06
Dec 31, 2021 -1.01
Sep 30, 2021 -1.14
Jun 30, 2021 -1.49
Mar 31, 2021 -3.51
Dec 31, 2020 -52.00
Sep 30, 2020 -41.15
Mar 31, 2020 -509.00
API Access

Nexgel Interest Coverage Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-coverage-ratio&ticker=NXGL&period=max&api_key=YOUR_API_KEY